HRP20170028T1 - Derivat morfolinonukleinske kiseline - Google Patents
Derivat morfolinonukleinske kiseline Download PDFInfo
- Publication number
- HRP20170028T1 HRP20170028T1 HRP20170028TT HRP20170028T HRP20170028T1 HR P20170028 T1 HRP20170028 T1 HR P20170028T1 HR P20170028T T HRP20170028T T HR P20170028TT HR P20170028 T HRP20170028 T HR P20170028T HR P20170028 T1 HRP20170028 T1 HR P20170028T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- salt
- general formula
- image
- following general
- Prior art date
Links
- -1 Morpholino nucleic acid Chemical class 0.000 title claims 7
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- IVSXFFJGASXYCL-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=NC=N[C]21 IVSXFFJGASXYCL-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 125000005002 aryl methyl group Chemical group 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000003738 guanin-9-yl group Chemical group O=C1N([H])C(N([H])[H])=NC2=C1N=C([H])N2[*] 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (6)
1. Spoj, naznačen time što ga prikazuje sljedeća opća formula (1), ili njegova sol:
[image]
,
gdje R1 predstavlja vodik ili skupinu koju prikazuje sljedeća opća formula (2):
[image]
,
(gdje * predstavlja mjesto vezanja;
R11, R12, R13 su isti ili različiti i svaki predstavlja vodik, alkil ili alkoksi)
R2 predstavlja skupinu koju prikazuje sljedeća opća formula (3) ili (4):
[image]
,
(gdje je * definiran kao što je opisano gore;
R4 predstavlja alkil, arilmetil ili ariloksimetil;
R5, R6 su isti ili različiti i svaki predstavlja alkil)
R3 predstavlja hidroksi skupinu, koja može biti zaštićena trialkilsililom ili difenilalkilsililom, ili skupinom koju prikazuje sljedeća opća formula (5):
[image]
,
(gdje je * definiran kao što je opisano gore;
X predstavlja O ili S;
Y predstavlja dialkilamino ili alkoksi;
Z predstavlja halogen).
2. Spoj, ili njegova sol, u skladu s patentnim zahtjevom 1, naznačen time što je X O, Y je dialkilamino, a Z je klor.
3. Spoj, ili njegova sol, u skladu s patentnim zahtjevom 1, naznačen time što R3 je hidroksi skupina, koja može biti zaštićena t-butildimetilsililom ili t-butildifenilsililom.
4. Spoj, ili njegova sol, u skladu s patentnim zahtjevom 1, naznačen time što je R4 fenoksimetil.
5. Spoj, ili njegova sol, u skladu s patentnim zahtjevom 1, naznačen time što R1 je tritil, 4-metoksitritil, 4-metiltritil, 4,4′-dimetiltritil, 4,4′-dimetoksitritil ili 4,4′,4″-trimetiltritil.
6. Spoj, naznačen time što ga se bira između sljedećih (1) do (3), ili njihovih soli:
(1) N9-[(2R,6S)-6-{(tert-butildimetilsililoksi)metil}-4-tritilmorfolin-2-il]-N2-(fenoksiacetil)-O6-(2-cijanoetil)gvanina,
(2) N9-{(2R,6S)-6-hidroksimetil-4-tritilmorfolin-2-il}-N2-(fenoksiacetil)-O6-(2-cijanoetil)gvanina,
(3) [(2S,6R)-6-{N2-(fenoksiacetil)-O6-(2-cijanoetil)guanin-9-il}-4-tritilmorfolin-2-il]metil-dimetilfosforoamidokloridata.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010220865 | 2010-09-30 | ||
| PCT/JP2011/072407 WO2012043730A1 (ja) | 2010-09-30 | 2011-09-29 | モルホリノ核酸誘導体 |
| EP11829283.8A EP2623507B1 (en) | 2010-09-30 | 2011-09-29 | Morpholino nucleic acid derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170028T1 true HRP20170028T1 (hr) | 2017-03-24 |
Family
ID=45893168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170028TT HRP20170028T1 (hr) | 2010-09-30 | 2017-01-10 | Derivat morfolinonukleinske kiseline |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8969551B2 (hr) |
| EP (1) | EP2623507B1 (hr) |
| JP (1) | JP5831455B2 (hr) |
| KR (1) | KR101764462B1 (hr) |
| CN (1) | CN103154009B (hr) |
| CA (1) | CA2813183C (hr) |
| CY (1) | CY1118435T1 (hr) |
| DK (1) | DK2623507T3 (hr) |
| ES (1) | ES2607603T3 (hr) |
| HR (1) | HRP20170028T1 (hr) |
| HU (1) | HUE030292T2 (hr) |
| LT (1) | LT2623507T (hr) |
| PL (1) | PL2623507T3 (hr) |
| PT (1) | PT2623507T (hr) |
| RS (1) | RS55610B1 (hr) |
| SI (1) | SI2623507T1 (hr) |
| SM (1) | SMT201700038B (hr) |
| WO (1) | WO2012043730A1 (hr) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47769E1 (en) | 2004-06-28 | 2019-12-17 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| WO2006086667A2 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| EP2350281B1 (en) | 2008-10-24 | 2014-05-14 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
| ES2693459T3 (es) | 2009-11-12 | 2018-12-11 | The University Of Western Australia | Moléculas antisentido y métodos para el tratamiento de patologías |
| CN107353317A (zh) * | 2010-05-28 | 2017-11-17 | 萨勒普塔医疗公司 | 具有修饰的亚基间键和/或端基的寡核苷酸类似物 |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| WO2013074834A1 (en) | 2011-11-18 | 2013-05-23 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
| CN104411831B (zh) | 2012-03-20 | 2020-08-11 | 萨勒普塔医疗公司 | 寡核苷酸类似物的硼酸缀合物 |
| CN102702265A (zh) * | 2012-05-14 | 2012-10-03 | 天津特安化学科技有限公司 | 一种固相合成磷酰二胺吗啉代寡核苷酸及方法 |
| IL293975A (en) | 2013-03-14 | 2022-08-01 | Sarepta Therapeutics Inc | Preparations that skip axon for the treatment of muscular dystrophy |
| CA2906812A1 (en) | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
| JP6477464B2 (ja) | 2013-05-24 | 2019-03-06 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
| IL300444A (en) | 2013-09-05 | 2023-04-01 | Sarepta Therapeutics Inc | Inclusion of exon 2 is induced by antisense in acid alpha-glucosidase |
| JP6901966B2 (ja) | 2014-05-16 | 2021-07-14 | オレゴン ステート ユニバーシティ | アンチセンス抗菌化合物および方法 |
| EP3569252B1 (en) | 2014-05-19 | 2021-12-15 | Oregon State University | Antisense antibacterial compounds and methods |
| JP6673211B2 (ja) * | 2014-10-14 | 2020-03-25 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
| EP3240794A4 (en) * | 2014-12-31 | 2018-10-31 | Oregon State University | Antisense antibacterial compounds and methods |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| HRP20231431T1 (hr) | 2015-05-19 | 2024-03-01 | Sarepta Therapeutics, Inc. | Peptidno oligonukleotidni konjugati |
| WO2016196670A1 (en) | 2015-06-01 | 2016-12-08 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
| EP3302489A4 (en) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES |
| EP4039690B1 (en) * | 2015-08-05 | 2024-07-17 | Eisai R&D Management Co., Ltd. | A substantially diastereomerically pure phosphoramidochloridate, a method and a pharmaceutical composition |
| JP2018530560A (ja) | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス， インコーポレイテッド | デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法 |
| JP2018538302A (ja) * | 2015-12-15 | 2018-12-27 | サレプタ セラピューティクス， インコーポレイテッド | ペプチドオリゴヌクレオチド複合体 |
| EP3394262B1 (en) | 2015-12-23 | 2024-08-28 | Oregon State University | Antisense antibacterial compounds and methods |
| AU2016379399B2 (en) | 2015-12-23 | 2022-12-08 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| AU2017254106B2 (en) | 2016-04-18 | 2024-07-11 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| AU2017258642B2 (en) | 2016-04-29 | 2023-08-31 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human LMNA |
| FI3464305T3 (fi) | 2016-05-24 | 2024-10-30 | Sarepta Therapeutics Inc | Menetelmiä oligomeerien valmistamiseksi |
| PT3464306T (pt) | 2016-05-24 | 2024-05-17 | Sarepta Therapeutics Inc | Processos para preparar oligómeros morfolino de fosforodiamidato |
| WO2017205880A1 (en) | 2016-05-24 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| SG11201809494VA (en) | 2016-05-24 | 2018-12-28 | Sarepta Therapeutics Inc | Pharmaceutical composition comprising eteplirsen |
| MA45362A (fr) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| JP7022079B2 (ja) | 2016-06-30 | 2022-02-17 | サレプタ セラピューティクス， インコーポレイテッド | ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス |
| CN109937042B (zh) * | 2016-09-20 | 2023-06-27 | 科罗拉多州立大学董事会法人团体 | 使用亚磷酰胺化学法合成主链修饰的吗啉代寡核苷酸和嵌合体 |
| JP2020517638A (ja) | 2017-04-20 | 2020-06-18 | エータイアー ファーマ， インコーポレイテッド | 肺の炎症を治療するための組成物および方法 |
| US20200362339A1 (en) * | 2017-09-25 | 2020-11-19 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis |
| JP7394753B2 (ja) | 2017-10-18 | 2023-12-08 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンスオリゴマー化合物 |
| EP3792269A4 (en) * | 2018-05-10 | 2022-06-22 | Nippon Shinyaku Co., Ltd. | PROCESS FOR PREPARING AN OLIGONUCLEIC ACID COMPOUND |
| WO2021025899A1 (en) | 2019-08-02 | 2021-02-11 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer pharmaceutical compositions |
| CN114981280A (zh) | 2019-11-13 | 2022-08-30 | 日本新药株式会社 | 寡核苷酸化合物的制造方法 |
| US20230018780A1 (en) * | 2019-11-13 | 2023-01-19 | Nippon Shinyaku Co., Ltd. | Method for producing oligonucleic acid compound |
| CN116096724A (zh) * | 2020-07-10 | 2023-05-09 | 常州合全药业有限公司 | 用于制备寡核苷酸的方法 |
| JPWO2022230954A1 (hr) * | 2021-04-28 | 2022-11-03 | ||
| KR20240004609A (ko) | 2021-04-30 | 2024-01-11 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근이영양증에 대한 치료 방법 |
| US20240318179A1 (en) | 2021-10-22 | 2024-09-26 | Murdoch University | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| EP4458833A1 (en) | 2021-12-27 | 2024-11-06 | Nippon Shinyaku Co., Ltd. | Method for producing oligonucleic acid compound |
| WO2023167908A1 (en) * | 2022-03-01 | 2023-09-07 | Eisai R&D Management Co., Ltd. | Bis-protected, activated guanine monomers |
| WO2023178230A1 (en) | 2022-03-17 | 2023-09-21 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
| WO2023205451A1 (en) | 2022-04-22 | 2023-10-26 | Entrada Therapeutics, Inc. | Cyclic peptides for delivering therapeutics |
| WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991009033A1 (en) | 1989-12-20 | 1991-06-27 | Anti-Gene Development Group | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
| JP2005255530A (ja) * | 2004-03-09 | 2005-09-22 | Japan Science & Technology Agency | ２−チオウリジン誘導体 |
| LT2735568T (lt) * | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| US8076476B2 (en) * | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| DK2207779T3 (da) | 2007-11-15 | 2014-07-14 | Sarepta Therapeutics Inc | Fremgangsmåde til syntese af morpholinooligomerer |
-
2011
- 2011-09-29 JP JP2012536551A patent/JP5831455B2/ja active Active
- 2011-09-29 SI SI201131069A patent/SI2623507T1/sl unknown
- 2011-09-29 PT PT118292838T patent/PT2623507T/pt unknown
- 2011-09-29 KR KR1020137011017A patent/KR101764462B1/ko active IP Right Grant
- 2011-09-29 WO PCT/JP2011/072407 patent/WO2012043730A1/ja active Application Filing
- 2011-09-29 LT LTEP11829283.8T patent/LT2623507T/lt unknown
- 2011-09-29 ES ES11829283.8T patent/ES2607603T3/es active Active
- 2011-09-29 DK DK11829283.8T patent/DK2623507T3/da active
- 2011-09-29 PL PL11829283T patent/PL2623507T3/pl unknown
- 2011-09-29 CA CA2813183A patent/CA2813183C/en active Active
- 2011-09-29 EP EP11829283.8A patent/EP2623507B1/en active Active
- 2011-09-29 HU HUE11829283A patent/HUE030292T2/en unknown
- 2011-09-29 US US13/876,194 patent/US8969551B2/en active Active
- 2011-09-29 CN CN201180047487.3A patent/CN103154009B/zh active Active
- 2011-09-29 RS RS20170057A patent/RS55610B1/sr unknown
-
2017
- 2017-01-10 CY CY20171100027T patent/CY1118435T1/el unknown
- 2017-01-10 HR HRP20170028TT patent/HRP20170028T1/hr unknown
- 2017-01-19 SM SM201700038T patent/SMT201700038B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2623507A4 (en) | 2014-03-19 |
| JPWO2012043730A1 (ja) | 2014-02-24 |
| CY1118435T1 (el) | 2017-06-28 |
| KR101764462B1 (ko) | 2017-08-02 |
| US20130197220A1 (en) | 2013-08-01 |
| ES2607603T3 (es) | 2017-04-03 |
| WO2012043730A1 (ja) | 2012-04-05 |
| CA2813183C (en) | 2017-09-19 |
| CA2813183A1 (en) | 2012-04-05 |
| RS55610B1 (sr) | 2017-06-30 |
| LT2623507T (lt) | 2017-01-25 |
| CN103154009B (zh) | 2015-06-10 |
| PL2623507T3 (pl) | 2017-03-31 |
| PT2623507T (pt) | 2016-12-23 |
| SMT201700038B (it) | 2017-03-08 |
| DK2623507T3 (da) | 2017-01-02 |
| CN103154009A (zh) | 2013-06-12 |
| HUE030292T2 (en) | 2017-04-28 |
| US8969551B2 (en) | 2015-03-03 |
| SI2623507T1 (sl) | 2017-04-26 |
| EP2623507B1 (en) | 2016-11-02 |
| JP5831455B2 (ja) | 2015-12-09 |
| KR20130143045A (ko) | 2013-12-30 |
| EP2623507A1 (en) | 2013-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170028T1 (hr) | Derivat morfolinonukleinske kiseline | |
| HRP20190824T1 (hr) | Heterociklilamini kao inhibitori pi3k | |
| RS54894B1 (sr) | Derivati benzotiofena supstituisani piperazinom kao antipsihotipna sredstva | |
| MX2014011829A (es) | Compuestos de piridinilideno n-sustituidos y derivados para combatir plagas de animales. | |
| PE20142345A1 (es) | Compuestos beta-lactamicos sustituidos con amidina, su preparacion y uso como agentes antibacterianos | |
| EA201590281A1 (ru) | Новые гетероарильные и гетероциклические соединения, их композиции и способы | |
| RS54892B1 (sr) | Agensi za indukciju apoptoze za lečenje karcinoma i imunskih i autoimunskih bolesti | |
| JP2010504286A5 (hr) | ||
| PH12014501488A1 (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| PE20191204A1 (es) | Modificador del sabor dulce | |
| EA201591537A1 (ru) | Производные бензотиофена и композиции, их содержащие, в качестве селективных супрессоров эстрогеновых рецепторов | |
| JP2013521295A5 (hr) | ||
| JP2013540755A5 (hr) | ||
| MY163498A (en) | Certain amino-pyrimidines, compositions thereof, and methods for their use | |
| NZ603643A (en) | Purinone derivative | |
| GEP201706774B (en) | Heterocyclyl compounds | |
| MX343264B (es) | Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos. | |
| EA201490579A1 (ru) | Новые хиральные n-ацил-5,6,7,(8-замещенные)тетрагидро-[1,2,4]триазоло[4,3-а]пиразины как селективные антагонисты рецептора nk-3, фармацевтическая композиция, способы применения при нарушениях, опосредованных nk-3 рецепторами, и их хиральный синтез | |
| EA201000614A1 (ru) | Производные пурина как лиганды аденозинового рецептора а | |
| MX2014011752A (es) | Compuestos heterobiciclicos n-sustituidos y derivados para combatir plagas de animales ii. | |
| MX2014011995A (es) | Compuestos de furanona heterobicíclicos n-sustituidos y derivados para combatir plagas de animales. | |
| EA201391056A1 (ru) | Гетероарильные соединения в качестве лигандов 5-htрецептора | |
| PL3077390T3 (pl) | Krystaliczna postać soli (s)-(2-(6-chloro-7-metylo-1h-benzo[d]imidazol-2-ilo)-2-metylopirolidyn-1-ylo)(5-metoksy-2-(2h-1,2,3-triazol-2-ilo)fenylo)metanonu jako antagonista receptora oreksyny | |
| MY160882A (en) | Biocidal composition and method | |
| AR061455A1 (es) | Acidos fosfinicos y sus derivados de azufre y metodos para su preparacion |